#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

First bio­similar adalimumab –  SB5


Authors: Lukáš M.
Authors‘ workplace: Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F., a.  s., Praha
Published in: Gastroent Hepatol 2018; 72(6): 551-552
Category:


Sources

1. Lee N, Lee JJ, Yang H et al. Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab. MAbs 2018; 1–16. doi: 10.1080/19420862.2018.1530920.

2. Frampton JE. SB5: An adalimumab bio­similar. BioDrugs 2018; 32(5): 507–510. doi: 10.1007/s40259-018-0307-0.

3. Weinblatt ME, Baranauskaite A, Dokoupilova E et al. Switch­­ing from reference adalimumab to SB5 (Adlimumab bio­similar) in patients with reumatoid arthritis: fifty-two-week phase 3 randomized study results. Arthritis Rheumatol 2018; 70(6): 832–840. doi: 10.1111/irv.40444.

Labels
Paediatric gastroenterology Gastroenterology and hepatology Surgery

Article was published in

Gastroenterology and Hepatology

Issue 6

2018 Issue 6

Most read in this issue
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#